Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
| 13.82 | |
| 14.04 | |
| - | |
| 14.42 | |
| 13.27 | |
| 4.69-20.9 | |
| 616 M | |
| 44 570 K | |
| 86 546 K | |
| -0.21 | |
| 0.699 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
We recently compiled a list of the Top 10 Holdings of Caligan Partners.In this article, we are going to take a look at where Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) stands against Caligan Partners' ot...
We can readily understand why investors are attracted to unprofitable companies. For example, Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders have done very well over the last year, with the share pric...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
